The clinical efficacy and safety as well as the application range of gene therapy will be broadened by developing systems capable of finely modulating the expression of therapeutic genes. Transgene regulation will be crucial for maintaining appropriate levels of a gene product within the therapeutic range, thus preventing toxicity. Moreover, the possibility to modulate, stop or resume transgene expression in response to disease evolution would facilitate the combination of gene therapy with more conventional therapeutic modalities. The development of ligand-dependent transcription regulatory systems is thus of great importance. Here, we summarize the most recent progress in the field.
In brief Progress
Encouraging progress has been made toward the generation of ligand-dependent transcription systems suitable for application in human gene therapy The latest versions of the Tet-ON system are not leaky Nonimmunosuppressive rapamycin analogs can be used to modulate the activity of dimerizer-regulated systems The dynamic range of the RU486-inducible switch has been increased A novel humanized steroid receptor-based regulatory system enables gene regulation in muscles Ecdysone-responsive regulatory systems that do not require R Â R coexpression may prove useful for gene therapy Inducible switches based on quorum-sensing systems have been generated Two transcription systems have been constructed, which are induced by streptogramin and macrolide antibiotics, respectively Conditional zinc-finger-based transcription factors can be used to regulate endogenous genes
Prospects
Transcription switches for gene therapy will be validated for safety and immunogenicity in large animal models Inducer ligands will be optimized for oral bioavailability, biodistribution, drug metabolism and toxicity Gene switches linked to zinc-finger technology will be evolved to modulate transcription of endogenous genes Ligand-inducible switches will be adapted to regulate small interfering RNAs sequences, to a transcription activation domain (AD) and to a domain that interacts with the inducer drug; (B) an artificial promoter consisting of multimeric-binding sites for the DBD followed by a minimal promoter. The chimeric transcription factor is recruited to (or in some cases released from) the specific target promoter upon interaction with the exogenously added drug: transcription of a transgene cloned downstream of this promoter can thus be modulated in vivo by systemic delivery or withdrawal of the inducer drug.
To be used in human gene therapy, a pharmacologically regulated system should fulfill several criteria: (1) ON switch. The ligand should activate (ON-switch) rather than silence transcription (OFF-switch). OFF-systems suffer from two drawbacks: a prolonged exposure to the drug is required to silence the system and the induction kinetics is mainly determined by the rate of drug clearance; (2) Specificity: the system should not interfere with endogenous metabolic pathways; (3) Bioavailability: the inducer drug should be orally bioavailable and penetrate all tissues; (4) Safety: the inducer compound should have a drug metabolism profile compatible with prolonged therapeutic use; (5) Reversibility: transcription should be fully and rapidly reversible to enable prompt changing of the dosing regimen; (6) Low basal activity and high inducibility: the system should be inactive in the absence of the inducer drug but strongly stimulated by drug administration; (7) Dose dependence: a precise correlation must exist between drug dosage and target gene expression level; (8) Low immunogenicity: the transcriptional activator(s) should exhibit a low potential of eliciting an immune response in humans.
Various ligand-dependent systems with potential for gene therapy have been generated in the past. Here, we report the most recent improvements they have been subjected to in order to meet the criteria listed above. We will also briefly describe some recently generated systems that have not been tested yet in animal models but are nonetheless of potential interest for gene therapy.
The latest versions of the Tet-ON system are not leaky
The tet-system is based on TetR, a procaryotic dimeric DNA-binding protein that binds to specific operator sequences (called tetO) of the tet-resistance operon. Tetracycline (Tc) or its more potent analog Doxycycline (Dox) binds to TetR and induces an allosteric change, which results in releasing the repressor from its target DNA sequence. 1 Fusing tetR with the VP16 activation domain resulted in a ligand-regulated transactivator, called tTA, which activated transcription from a tet-responsive promoter in the absence of Dox (Figure 1a ). This 'Tet-OFF' system has been widely used in animal models but, because of its unfavorable kinetic properties, is unlikely to move from the preclinical to the clinical setting. 1 Mutagenesis of tTA resulted in a reverse tTA (rtTA) that stimulates transcription only upon ligand addition (Figure 1b) . This Tet-ON system suffered from two major drawbacks: it was fully active only at high Dox doses and displayed a significant basal activity, mainly due to the residual binding of rtTA to tetO in the absence of the inducer ligand. 1 The Tet-ON system has recently been greatly improved for basal activity, inducibility and Dox responsiveness. A major progress has been the isolation of two novel rtTA variants, called rtTA2 S -S2 and rtTA2 S -M2: they retain Dox dependency but display a considerably lower basal activity in the OFF state. 2 They also have a codon-optimized sequence, resulting in improved expression and stability, and carry a minimal transactivation domain called VP16-F3, consisting of three tandem repeats of a 12 amino acid peptide derived from VP16.
rtTA2
S -S2 displays an uninduced activity slightly lower than rtTA2 S -M2 that, however, has the distinct advantage of being about 10-fold more sensitive to Dox. 2, 3 Both novel transactivators proved capable of tightly Figure 1 Schematic representation of the various versions of the tetsystem. (a) tTA-based, Tet-OFF system. tTA is a fusion between TetR and an activation domain (VP16 or VP16-F3). In the absence of Dox, tTA binds to and activates a minimal TATA box-containing promoter located downstream of multiple tet operator (tetO) sites. Upon addition of Dox, tTA is released from DNA and the promoter becomes inactive. (b) rtTAbased, Tet-ON system. rtTA is a fusion between a reverse TetR (rTetR) and an activation domain: it binds and activates the target promoter upon Dox administration. (c) rtTA/tTS-based system. tTS consists of TetR fused to the KRAB repressor domain. In the absence of Dox, tTS binds and represses the target promoter. Upon drug administration, tTS is released from DNA, while rtTA binds and activates the promoter. More stringent control was obtained by incorporating a Dox-dependent trans-silencer, called tTS, in the Tet-ON system. tTS consists in the KRAB (Kruppel-Associated Box) transrepressing domain of human Kid-1 protein fused to the wt TetR. 6, 9 Coexpressing rTA with a tTS unable to heterodimerize with rtTA results in very tight regulation. 1 In the absence of Dox, tTS binds to tetO and inhibits basal transcription; as Dox is added, tTS dissociates from the target DNA while rtTA becomes active and triggers transcription (Figure 1c) . Indeed, rtTA/tTS dual systems significantly reduced the basal expression of target transgenes in vivo, provided that vector architecture was optimized. 7, 8 Finally, the latest and most improved versions combine tTS with rtTA2 S -S2 and rtTA2 S -M2. 6, 9, 10 Various bicistronic cassettes coexpressing via internal ribosome entry site (IRES) tTS and rtTA or rtTA2 S -S2 or rtTA2 S -M2 (IRES-A, IRES-S2 and IRES-M2 systems, respectively) have been constructed. Both IRES-S2 and IRES-M2 displayed a negligible baseline activity and a 10-fold expanded dynamic range of induction than IRES-A: IRES-M2 also displayed an enhanced Dox-sensitivity. 9 When delivered into mouse muscles in the context of plasmid or gutless-Ad vectors, the IRES-M2 expression cassette mediated very tight and strictly Dox-dose-dependent modulation of expression for more than 1 year. 6, 9 In agreement with these findings, Ad-vectors containing distinct expression cassettes for rtTA2 S -S2, tTS and the transgene of interest display greatly improved Dox-inducible gene expression in terms of basal activity and drug responsiveness. 10 The Tet-system is apparently not immunogenic in several mouse strains; in contrast, recent studies indicate that intramuscularly delivered Tet-ON activators may elicit a cellular and humoral response in non-human primates. 11, 12 More studies will be required to clarify the potential for immunogenicity in humans.
Dox is orally bioavailable, has a half-life of 14-22 h, has an excellent tissue penetration (it also penetrates the blood-brain barrier) and is largely eliminated by the intestinal way, thus rendering this drug useful in the case of renal disfunction. 13 The finding that the latest Tet-ON versions are fully induced in rodents and monkeys by Dox dosing regimens comparable to that commonly used for antibiotic therapy is thus of great interest. 9 Dox is well tolerated, at least for short-to medium-term (ie months) applications: the most serious side effect is a dose-dependent photosensitivity that may occur in 1-3% of the patients after prolonged administration. 13 Dox accumulates in the bones and may thus cause yellowbrown coloration of the teeth; its slow release from bones may potentially slow down the silencing of the Tet-ON systems. However, the major concern with respect to the use of an antibiotic-driven regulatory switch remains the possibility of raising resistance to the antibiotic itself. Indeed, Tcs are less used than in the past, but may still represent the treatment of choice for diseases like Lyme disease and Rickettsial disease. 13 The generation of Tetsystem stimulating, nonantibiotic Dox analogs would thus be desirable.
The Tet-ON system has proved to be highly flexible and we can thus expect novel versions to be available in the future. A recent example is the generation of singlechain (sc) tet transregulators consisting of the two monomers of the dimeric TetR connected by a 20 amino-acid linker and fused with a single activating or repressing domain.
14 This may lead to the generation of a novel series of regulators.
Nonimmunosuppressive rapamycin analogs can be used to modulate the activity of dimerizer-regulated systems Dimerizer-regulated systems are based on the use of small molecules with distinct binding surfaces for two different polypeptides. 15 Rapamycin is the prototype molecule: it mediates heterodimer formation between the immunophilin FKBP12 (FK506-binding protein of 12 kDa) and the FRB (FKBP rapamycin-binding) domain of FRAP (FKBP rapamycin-associated protein), a phosphoinositide 3-kinase. By fusing FKBP to a DBD and FRB to an AD, the assembly of an active transcription factor will be strictly dependent on the presence of rapamycin. 15 The rapamycin-inducible system was originally designed to be composed only of elements of human origin, to reduce its potential immunogenicity. In its more classical configuration, the DNA-binding element is ZFDH1-FKBP, where ZFDH1 (zinc-finger homeodomain fusion) consists of a zinc-finger pair and a homeodomain, while the activating element is FRB-p65, where p65 is the activating domain of the p65 human protein.
15
ZFDH1-FKBP and FRB-p65 associate only in the presence of rapamycin and trigger transcription from a ZFDH1-dependent promoter (Figure 2a) . The rapamycin-inducible system has a low basal activity because of the physical separation of the DBD and the AD, and a high degree of inducibility. 16 The system has been recently improved in terms of inducibility and drug responsiveness by including a more potent AD consisting of two sequential activation domains, namely those of human p65 and of HSF1 (human heat shock factor 1, see also legend to Figure 2a) . 17 Tightly controlled and highly inducible expression was demonstrated in mouse and macaque eyes as well as in mouse liver following AAV and adenoviral gene transfer, respectively. 18, 19 Furthermore, a regulated macaque erythropoietin (Epo) gene delivered with AAV vectors in the muscle of rhesus macaques could be repeatedly induced upon systemic drug delivery. 15 Although in initial studies three out of six primates tested underwent expression shut-off, in a later trial involving eight animals injected with the improved system all of them showed persistent expression. 15 This may suggest that the shut-off observed in the first study was not due to immunological response against the activators but due to decreased expression of the transactivators over time.
The pharmacologic and pharmacodynamic properties of rapamycin are very well known. 20 Interestingly, rapamycin has a relatively short half-life of about 4.5 h but shut-off of gene expression in response to drug Transcription regulatory systems C Toniatti et al withdrawal is a slow process that occurs several days after administration of a single dose of rapamycin. 15 This is probably a consequence of the strong stability of the transcription activating complex assembled by the drug. Daily administration of the drug is thus not necessary to maintain the system in the on state; on the other hand, the system cannot be promptly silenced by drug withdrawal. The major drawback of this system is the immunosuppressing activity of rapamycin, which is due to binding and inhibition of FRAP. 20 Rapamycin is only partially orally bioavailable and this explains why it has been administered by intraperitoneal administration in the great majority of published studies. Therefore, highly immunosuppressive oral doses would be required to stimulate strongly the system in humans, thus rendering this version of the system impractical for clinical applications.
More recently, however, the three-dimensional structure of the ternary complex FKBP-rapamycin-FRB helped to redesign the binding interface of rapamycin with FRB to generate FRB variants capable of binding nonimmunosuppressant rapamycin analogs (rapalogs) carrying a substitution at the C16 or C7 positions. 15 Although their structure has not yet been disclosed, they are supposed to act in combination with a single amino-acid-substituted FRB-T2098L. This variant and some of its corresponding rapalogs AP22565 and AP21967 efficiently induced gene expression in cell lines transduced with a retroviral vector or in vivo in tumors injected with adenoviral vectors. 15, 21 Based on these results, the solution to immunosuppression seems to be at hand. However, the changes in the structure of rapamycin may dramatically affect pharmacology and drug metabolism. As a matter of fact, so far no transcription-specific rapalog has been reported with a defined oral bioavailability and pharmacokinetic.
A system similar to that induced by rapamycin has been described with nonimmunosuppressive analogs of The inducible transcription factor consists of a DBD (such as GAL4 or HNF-1) fused to a mutant HBD, which does not interact with endogenous steroids but is still able to bind synthetic analogs, and to an activation domain, such as p65. DC42 and DC19 indicate the 42-amino acid and the 19-amino-acid C-terminal deletions or PR-HBD, respectively, which specifically interact with RU486. G521R indicates the ER-HBD point mutant that binds to 4-OHT. The chimera is constitutively bound to the hsp90 (heat-shock protein 90) complex and therefore inactive. Upon addition of the appropriate drug (such as RU486 and 4-OHT for the PR-HBD and the ER-HBD mutants, respectively), the chimera is released from the hsp90 complex and then interacts with its binding sites in the target promoter. See text for additional details.
Transcription regulatory systems C Toniatti et al FK506. 22 Likewise, efforts in synthetic chemistry led to the generation of fusion compounds between methotrexate and a synthetic FKBP ligand or between methotrexate and dexamethasone, which trigger the formation of heterodimerizers between dihydrofolate reductase (DHFR) and FKBP12 or between DHFR and the glucocorticoid receptor, respectively. 23, 24 One can envisage that the extensive use of combinatorial chemistry, coupled with protein design, will trigger in the future an explosion of dimerizer-regulated systems.
The dynamic range of the RU486-inducible switch has been increased Heterologous proteins can be rendered hormone responsive by fusing them with the hormone-binding domain (HBD) of steroid receptors. This strategy has been applied to generate chimeric activators equipped with mutant HBDs that do not interact with natural steroids but only bind to synthetic analogs.
The best-characterized system is regulated by RU486, a synthetic progesterone (PR) antagonist, also known as mifepristone. 25 In its prototype configuration, the RU486-dependent chimera comprises the DBD of the yeast transcription factor GAL4, a heterologous AD and a C-terminally deleted PR-HBD, that selectively binds RU486 but not progesterone (Figure 2b) . 26 Over the past decade, the system has been improved in terms of potency, drug-responsiveness and leakiness by using ADs derived from p65, by inserting different deletions of the PR-HBD and by introducing substitutions within the GAL4-DBD. The latest version of the system, which is now commercialized with the registered trademark GeneSwitch s , strongly induces transcription, responds to very low (10 À10 M) concentrations of RU486 but may display a significant basal activity. 26, 27 RU486 inducible expression of transgenes has been documented in animal models of gene therapy. A suboptimal version of the activator enabled long-term regulation of the human growth hormone (hGH) expression upon delivery in mice liver with a helperdependent adenoviral vector. 28 The system also enabled transgene regulation upon delivery into skeletal muscle as plasmid DNA in this setting however, it did not prove very potent in that a high amount of plasmid had to be injected in order to observe a significant induction of transgene expression. 29, 30 Nonetheless, intramuscular delivery of GeneSwitch s -based plasmids may represent a powerful approach for the therapeutic induction of proteins displaying a high-specific activity, such as growth hormone releasing hormone (GHRH). 31 In an attempt to reduce the leakiness of the system and to increase the dynamic range of induction, an autoinducible GeneSwitch s system was generated. This displays a lower basal activity and a higher foldinduction; however, maximum expression levels are lower than those obtained from more conventional constructs. 27 A further improved version of transactivator, called GS4, has been recently described: it carries a shorter version of the GAL4 DBD and has a lower basal activity as a consequence of the reduced capability to homodimerize in the absence of the ligand.
26
RU486 promptly activates GeneSwitch s : in general, transgene product is already detectable 3 h after administration of a single dose. 28 RU486 is approved in several countries in combination with prostaglandins as a treatment to terminate pregnancy. 32 Dose-response experiments have been performed in mice: a comparison between the pharmacokinetic properties of RU486 in mice and humans suggests that GeneSwitch s would be maximally stimulated in human by oral doses at least one order of magnitude lower than those required to induce abortion (about 200-600 mg). Nonetheless, these lower dosages may affect the ovarian cycle and exert a contraceptive activity. 32 Therefore, a novel inducer unable to interact with endogenous PR would be more appropriate for clinical use in gene therapy.
A novel humanized steroid receptor-based regulatory system enables gene regulation in muscles HBD-based chimeric activators containing the yeast GAL4 DBD may be immunogenic in humans and therefore of limited efficacy for long-term gene therapy. In theory, however, customized HBD-based molecular switches, which make use of human DBDs and effectively regulate gene expression in selected tissues, can be constructed. To this aim, two requirements must be fulfilled: first, the DBD must be derived from a transcription activator that is not expressed in the target cell/tissue; second, the inducible gene must be placed under the control of a synthetic promoter that carries only binding sites for that specific DBD. According to this strategy, a fully humanized HBD-based activator (called HEA-3) specifically designed to work in muscle cells has been recently described. 33 HEA-3 is composed of three elements: the DBD derives from transcription factor hepatocyte nuclear factor 1 (HNF1), a dimeric homeoprotein expressed in hepatocytes and in a few other epithelial cells, but not in muscle. This DBD was fused to a G(521)R mutant of the estrogen receptor HBD (ER-HBD), which binds the synthetic antiestrogen 4-hydroxytamoxyfen (4-OHT) but not estradiol, and to the human p65 activation domain. 33 HEA-3 responsive promoters consisting of multimeric HNF-1-binding sites were silent in cultured cells lacking endogenous HNF1a but were strongly activated by HEA-3 in a stringent 4-OHT-dependent manner (Figure 2b ). Upon delivery as plasmid DNA in mouse muscles, HEA-3 was induced by oral doses of Tamoxifen (TAM), which is converted into the active metabolite 4-OHT in vivo. In particular, HEA-3 enabled 100-fold induction of secreted alkaline phosphatase (SEAP) gene expression and long-term modulation of Epo expression in mice. 33 TAM is a clinically validated drug that is currently used for the treatment of hormone-dependent breast cancer; however, in its present format the HEA-3 system is not highly responsive to this drug. In fact, doseresponse experiments in mice indicated that TAM dosages higher than those used in the clinical practice would be required to stimulate fully the HEA-3 system in humans. 33, 34 Moreover, prolonged treatments with TAM are associated with various side effects, including thromboembolic phenomena, a low increased risk of endometrial cancer as well as hot flashes. 35 Therefore, as for GeneSwitch s , inducer drugs that do not have any effect on endogenous proteins would be more appropriate. Future work should focus on redesigning the HBD-hormone interface in order to differentiate it from Transcription regulatory systems C Toniatti et al endogenous receptors, and to identify novel ligands that only bind to those mutated HBDs.
The combined use of tissue-specific DBDs and mutant HBDs might generate a whole series of 'customized' chimeras, specifically designed to work in a restricted range of cells. Such molecular switches might recognize DNA sites within the chromosomes thus affecting endogenous gene expression. DNA microarray technology or whole-cell proteomics will help to clarify this safety issue.
Ecdysone-responsive regulatory systems that do not require R Â R coexpression may prove useful for gene therapy
The steroid hormone ecdysone plays a fundamental role during insect molting and metamorphosis: it acts by stimulating a transcription factor, the ecdysone receptor (EcR). 36 The functional EcR is a non-covalent heterodimer with the insect protein ultraspiracle (USP). EcR carries a transcriptional silencer in its ligand-binding domain: binding of the cognate ligand induces a conformational change that makes the co-repressor dissociate from the receptor and recruits activators, resulting in transcriptional activation of genes under EcR control. 36 Responsiveness to ecdysone was recreated in cells by cotransfecting Drosophila melanogaster EcR (DmEcR) and USP with an EcR-responsive gene; however, transgene stimulation was poor. More potent systems were subsequently generated, which are based on variably modified EcR and use the retinoid-X-receptor (R Â R), the mammalian counterpart of USP, as the dimerizing partner. [37] [38] [39] These switches are induced in cultured cells by Muristerone A (murA) and Ponasterone A (PonA), more potent effectors isolated from plants. Among these new systems, RheoSwitch s , in its various versions, displays the lowest background activity coupled with a strong inducibility (up to 10 000-fold induction in cultured cells). 40, 41 Actually, RheoSwitch s has a two-hybrid format in that it relies on the coexpression in target cells of a GAL4-DBD fused to the EcR and a VP16-AD fused to the RÂR receptor. Notably, the EcR is a reluctant dimer partner for RÂR and efficient transactivation can only be achieved by overexpressing RÂR in the target cells. This poses a safety concern for gene therapy, considering the large number of metabolic pathways in which heterodimers containing RÂR are involved. The recent finding that RÂR overexpression in cardiomyocyte caused dilated cardiomyopathy in mice further emphasizes this aspect. 42 Moreover, natural ligands for RÂR, such as 9-cis-retinoic acid (9cRA), may modulate the activity of EcR agonists on the RÂR/EcR heterodimers. 38 Of interest was therefore the finding that EcR from Bombyx mori (BEcR) dimerizes much more efficiently with RÂR and is responsive to nonsteroidal agonists. Indeed, an advanced version of the system is based on a DmEcR-VP16 chimera fused to the hinge region and the HBD of BEcR. This hybrid-receptor (called DB-EcR) recognizes an unnatural DNA element (E/GRE sequence), does not require RÂR to induce gene expression in mammalian cells and responds more efficiently to nonsteroidal agonists. 43 The DB-EcR-based system has been delivered in vivo by intramyocardial injection of recombinant adenovirus vectors in rats and guineapigs. [43] [44] [45] In short-term experiments, this switch demonstrated a low basal activity and showed up to 40-fold induction of target luciferase transgene expression in response to GSE, a synthetic bisacylhydrazine. 43 Additional work in vivo is nonetheless awaited to clarify the potential of this system for gene therapy; notably, the sequestration of endogenous RÂR by DB-EcR could have deleterious effects that may only become evident in longterm studies.
Ecdysteroids are considered safe compounds because humans eat large amounts of phytoecdysteroids contained in vegetables without detrimental effects. 46 Nonetheless, more detailed toxicology data would be required in the light of their potential use in human gene therapy. Moreover, because of the dietary intake, the development of ecdysteroid-insensitive regulatory switches might be necessary. A family of bisacylhydrazines has been identified that mimics the activity of ecdysone on the EcR. 47 In a recent study, molecular modeling and sitedirected mutagenesis of the EcR were used to generate a mutant EcR that induces transcription of target genes in response to bisacylhydrazines but not to ecdysteroids. 48 This finding along with the recent demonstration that the Ecr-HBD exhibits an extreme flexibility (ie may adopt different binding pockets for different ligands) indicates that it should be possible to generate a series of EcRligand pairs to control multiple genes within the same target cells. 49 Inducible switches based on quorum-sensing systems have been generated A regulated transcription switch has recently been generated that is based on the cell-cell communication quorum sensing process. Quorum sensing in bacteria is based on a signal molecule, an acylated homoserine lactone (AHL), which accumulates in the immediate external environment, and a cognate transcription factor which it activates. 50 TraR belongs to the LuxR family of transcriptional activators. Binding the Agrobacterium tumefaciens quorum sensing signal 3-oxo-C8-HSL results in proper folding of TraR which becomes capable of binding an 18-bp long specific DNA sequence, called tra box. 51 Hybrid transcription factors were generated by fusing TraR with ADs functional in eukaryotic cells. These chimeric activators bound a tra box in vitro and efficiently activated transcription from TraR-responsive promoters in cultured cells only in the presence of a cognate ligand, such as 3-oxo-C8-HSL. 52 Notably, the ligand must be present during the synthesis of the chimera for proper folding: thus the system displays a very low activity in the absence of the inducer, but is limited by a substantial time-lag between cell exposure to AHL and gene activation. 52, 53 Interestingly, the chemically unstable lactone moiety present in all quorum-sensing signal molecules could be efficiently substituted by a more stable lactam moiety, indicating that the chemical properties of the inducer can be improved. 52, 54 Over 50 species of gram-negative bacteria produce AHLs that differ in the acyl side chain: the quorumsensing system thus represents a natural combinatorial Transcription regulatory systems C Toniatti et al library that could be exploited to generate a series of gene regulation systems. 50 The generation of an additional regulatory switch based on Streptomyces quorumsensing system further underlines the potential of this approach. 55 Two transcription systems have been constructed that are induced by streptogramin and macrolide antibiotics, respectively
Two further regulatory switches have recently been described that are based on naturally evolved mechanisms of antibiotic resistance. A first system is based on a Streptomyces pristinaespiralis repressor protein, called pristinamycin-induced protein (Pip), which binds to a Pip operator sequence: pristinamycin, a composite streptogramin antibiotic, binds to Pip and this results in the release of Pip from Pip operator. 56 Similar to the Tet-system, the pristinamycin-dependent Pip-Pip operator interaction was adapted for use in mammalian cells. Two configurations were developed: PipOFF and PipON, which rely on the use of Pip-Vp16 and Pip-KRAB fusion proteins and are silenced or activated by pristinamycin, respectively. 57 Another system regulated by macrolide antibiotics, such as erythromycin (EM), was developed. The key element derives from a procaryotic DNA-binding protein, called MphR(A), which binds to a 35-bp operator sequence. Upon binding to EM, MphR(A) dissociates from its target DNA sequence. 56 Very similar to the streptogramin system, Erythromycin OFF (E OFF ) and ON (E ON ) systems were obtained that rely on MphR(A)-VP16 and MphR(A)-KRAB chimeras, respectively. 58 The four systems (PipON, PipOFF, E OFF and E ON ) enable 100-fold induction of reporter gene expression in cultured cells and display a relatively low basal activity. They have been recently improved in terms of inducibility, potency and drug responsiveness and are compatible with the Tet-system. 59, 60 Another attractive feature is that they are activated by clinically approved drugs: it will thus be of interest to test their properties in animal models.
Conditional zinc-finger-based transcription factors can be used to regulate endogenous genes Engineered zinc-finger domains can potentially target any DNA sequence: when fused to activating or repressing domains, they can activate or block the expression of delivered transgenes as well as of endogenous genes. 61 In a further advanced version, regulated switches can be generated by adding the appropriate regulatory domain to the zinc-finger-based regulator. RU-486, TAM-and rapamycin-dependent activators containing zinc-fingers of predetermined specificity have been generated, which may target and therefore activate endogenous and transduced genes in cultured cells as well as in vivo. [62] [63] [64] [65] Although at its primordia, this strategy deserves particular attention because of its capability to modulate endogenous genes.
Prospects
The generation and refinement of ligand-induced transcription switches is an area of active investigation: longterm regulation of gene expression in humans may be a not-too-distant achievement. In the future, the possibility of regulating transgenes will likely impact various therapeutic areas. For instance, recent reports demonstrate the importance of regulatory switches to improve the safety of conditionally replicating adenoviral vectors and regulate the production of retroviruses from tumortargeted T cells. 21, 66 In addition, we can expect that regulated switches will be appropriately adapted to regulate small interfering RNAs production. [67] [68] [69] [70] Inducible siRNA vectors would represent powerful tools for both clinical application and generation of animal models of human diseases.
